BAL Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: BAL Pharma Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $5.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

BAL Pharma Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $5.4M Trade | TransData Nexus

Product Portfolio — Top 3 by Export Value

BAL Pharma Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gliclazide	Advanced Diabetes Medications	$2.6M	136	0.9%	10
2	Diclofenac	Analgesics & Antipyretics	$2.3M	45	0.6%	11
3	Griseofulvin	Advanced Antifungals	$634.0K	38	1.8%	8

BAL Pharma Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $5.4M. The top category is Advanced Diabetes Medications (47.0% of portfolio), followed by Analgesics & Antipyretics (41.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

BAL Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Bal Pharma Limited, established in 1987, is a prominent Indian pharmaceutical company headquartered in Bengaluru, Karnataka. The company specializes in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs), offering a diverse portfolio that includes prescription drugs, generics, over-the-counter (OTC) products, intravenous infusions, and bulk drugs.

As of March 2025, Bal Pharma reported a workforce of 715 employees. The company is publicly listed on the Bombay Stock Exchange under the ticker symbol 524824 and on the National Stock Exchange of India as BALPHARMA. In the fiscal year ending March 2025, Bal Pharma reported a revenue of approximately ₹2,348.39 million.

2Manufacturing Facilities

Bal Pharma operates six state-of-the-art manufacturing facilities across India, each specializing in different aspects of pharmaceutical production. Unit 1 in Bengaluru focuses on the production of tablets and capsules, with an annual capacity of 1.80 billion tablets and 200 million capsules. Unit 2, also in Bengaluru, is dedicated to the manufacturing of APIs, with an annual capacity of 60 tonnes of mixed products. Unit 3 in Pune specializes in intravenous fluids, ophthalmic preparations, and liquid oral preparations, with an annual capacity of 18 million vials, 6 million IV bottles, and 5 million syrup bottles. Unit 4 in Rudrapur focuses on tablets, capsules, creams, gels, and ointments, with an annual capacity of 1.80 billion tablets, 300 million capsules, and 20 million tubes. Unit 5 in Sangli is dedicated to the production of intermediates, and Unit 6 in Udaipur focuses on other pharmaceutical products.

3Key Leadership

The leadership team at Bal Pharma Limited is headed by Managing Director and Executive Director Shailesh Dheerajmal Siroya. The Chief Financial Officer is Daddanala Venkat Bharath Bhushan. Other key executives include Archana Dubey Mitra, serving as the Chief Operating Officer, and Himesh Virupakshaya, a Whole Time Director. The company also has a Deputy General Manager of Internal Audit, Legal and Compliance, Ravindra Kumar Kothari, and a Company Secretary and Compliance Officer, Abdul Basith.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does BAL Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bal Pharma Limited has made significant strides in entering regulated markets, particularly in the European Union (EU). The company's manufacturing facility in Rudrapur has received EU Good Manufacturing Practice (GMP) approval, indicating compliance with stringent EU standards. Additionally, the company has obtained approvals from various international regulatory bodies, including the Therapeutic Goods Administration (TGA) of Australia, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the Ministry of Health (MOH) of Canada, the Korea Food and Drug Administration (KFDA), and the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) of Mexico. These approvals facilitate Bal Pharma's market access in these regions, allowing the company to export its products to a broader international audience.

In the United States, Bal Pharma has filed a Drug Master File (DMF) for Bepotastine API with the U.S. Food and Drug Administration (FDA), demonstrating its commitment to meeting U.S. regulatory standards. This filing is a crucial step for the company to gain market access in the U.S., a key regulated market.

2Emerging Markets

Bal Pharma Limited has a strong presence in emerging markets, exporting its products to approximately 30 countries across Africa, Latin America, Southeast Asia, and the Middle East. The company's manufacturing facilities, such as Unit 3 in Pune, are approved by regulatory authorities in countries like Zimbabwe, Nigeria, and Yemen, enabling access to these markets. Additionally, the company's API and finished dosage forms (FDF) are exported to Europe, the Far East, Latin America, Africa, the Middle East, and other global markets, indicating a diversified export strategy.

BAL Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Bal Pharma Limited has taken steps to enter the U.S. market by filing a Drug Master File (DMF) for Bepotastine API with the U.S. Food and Drug Administration (FDA). This filing is a critical component for obtaining FDA approval and gaining market access in the United States. The company's manufacturing facilities have received approvals from various international regulatory bodies, including the TGA of Australia, the PMDA of Japan, the MOH of Canada, the KFDA, and COFEPRIS of Mexico, indicating a commitment to meeting global regulatory standards.

2WHO & EU GMP

Bal Pharma Limited's manufacturing facility in Rudrapur has received EU Good Manufacturing Practice (GMP) approval, demonstrating compliance with stringent EU standards. Additionally, the company's manufacturing facilities have received approvals from various international regulatory bodies, including the TGA of Australia, the PMDA of Japan, the MOH of Canada, the KFDA, and COFEPRIS of Mexico, indicating a commitment to meeting global regulatory standards.

3CDSCO & Indian Regulatory

BAL Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Bal Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on APIs and finished formulations, along with its diversified export strategy targeting emerging markets, positions it favorably in the global market. The company's manufacturing facilities have received approvals from various international regulatory bodies, including the TGA of Australia, the PMDA of Japan, the MOH of Canada, the KFDA, and COFEPRIS of Mexico, facilitating market access in these regions.

2Key Differentiators

Bal Pharma Limited's key differentiators include its diversified product portfolio, encompassing prescription drugs, generics, OTC products, intravenous infusions, and bulk drugs. The company's focus on APIs and finished formulations, along with its diversified export strategy targeting emerging markets, positions it favorably in the global market. The company's manufacturing facilities have received approvals from various international regulatory bodies, including the TGA of Australia, the PMDA of Japan, the MOH of Canada, the KFDA, and COFEPRIS of Mexico, facilitating market access in these regions.

3Strategic Position

Frequently Asked Questions — BAL Pharma Limited

How many pharmaceutical products does BAL Pharma Limited export from India?

BAL Pharma Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Gliclazide ($2.6M), Diclofenac ($2.3M), Griseofulvin ($634.0K). Total export value is $5.4M.

What is BAL Pharma Limited's total pharmaceutical export value?

BAL Pharma Limited's total pharmaceutical export value is $5.4M, based on 219 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does BAL Pharma Limited cover?

BAL Pharma Limited exports across 3 therapeutic categories. The largest are Advanced Diabetes Medications (47.0%, 1 products), Analgesics & Antipyretics (41.3%, 1 products), Advanced Antifungals (11.6%, 1 products).

Get Full BAL Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

BAL Pharma Limited

BAL Pharma Limited — Export Portfolio & Destination Treemap

Who is BAL Pharma Limited? — Company Overview & Market Position

What Does BAL Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

BAL Pharma Limited Therapeutic Categories — 3 Specializations